Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections

• Status: Completed
• Trial end date: 2019-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective randomized study comparing different colistin dosing regimens in paediatric cancer patient with MDR gram-negative infection or sepsis

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute, Egypt
• Treatments: Colistin; Polymyxins

Criteria

Inclusion Criteria:

1. Age between one year and 18 years

2. All paediatric cancer patients who are prescribed intravenous colistin due to:

• Sepsis due to MDR or minimally susceptible gram-negative bacteria

• History of MDR gram-negative infection or sepsis due to organisms sensitive to colistin.

• Culture result consistent with MDR gram negative for this febrile neutropenic episode.

• Patient in sepsis and colistin was administered empirically to increase antibiotic coverage.

Exclusion Criteria:

1. Age less than one year or over 18 years

2. Patients with renal impairment

3. Colistin use less than 72 hours